- Home
- HOWL
as of 12-30-2025 3:38pm EST
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 64.5M | IPO Year: | 2021 |
| Target Price: | $6.50 | AVG Volume (30 days): | 935.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.56 - $2.38 | Next Earning Date: | 11-04-2025 |
| Revenue: | N/A | Revenue Growth: | -90.55% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered HOWL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Werewolf Therapeutics Inc. (HOWL)
Director
Avg Cost/Share
$0.61
Shares
108,606
Total Value
$66,249.66
Owned After
2,550,674
SEC Form 4
Director
Avg Cost/Share
$0.63
Shares
35,632
Total Value
$22,448.16
Owned After
2,550,674
SEC Form 4
Director
Avg Cost/Share
$0.65
Shares
16,310
Total Value
$10,601.50
Owned After
2,550,674
SEC Form 4
Director
Avg Cost/Share
$0.63
Shares
71,428
Total Value
$44,999.64
Owned After
2,550,674
SEC Form 4
Director
Avg Cost/Share
$0.69
Shares
59,307
Total Value
$40,921.83
Owned After
2,550,674
SEC Form 4
Director
Avg Cost/Share
$1.14
Shares
9,983
Total Value
$11,380.62
Owned After
2,550,674
SEC Form 4
Director
Avg Cost/Share
$1.05
Shares
14,548
Total Value
$15,275.40
Owned After
2,550,674
SEC Form 4
Director
Avg Cost/Share
$1.07
Shares
23,640
Total Value
$25,294.80
Owned After
2,550,674
SEC Form 4
Director
Avg Cost/Share
$1.01
Shares
44,570
Total Value
$45,015.70
Owned After
2,550,674
SEC Form 4
Director
Avg Cost/Share
$0.99
Shares
34,041
Total Value
$33,700.59
Owned After
2,550,674
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| EVNIN LUKE | HOWL | Director | Dec 29, 2025 | Sell | $0.61 | 108,606 | $66,249.66 | 2,550,674 | |
| EVNIN LUKE | HOWL | Director | Dec 26, 2025 | Sell | $0.63 | 35,632 | $22,448.16 | 2,550,674 | |
| EVNIN LUKE | HOWL | Director | Dec 24, 2025 | Sell | $0.65 | 16,310 | $10,601.50 | 2,550,674 | |
| EVNIN LUKE | HOWL | Director | Dec 23, 2025 | Sell | $0.63 | 71,428 | $44,999.64 | 2,550,674 | |
| EVNIN LUKE | HOWL | Director | Dec 22, 2025 | Sell | $0.69 | 59,307 | $40,921.83 | 2,550,674 | |
| EVNIN LUKE | HOWL | Director | Dec 17, 2025 | Sell | $1.14 | 9,983 | $11,380.62 | 2,550,674 | |
| EVNIN LUKE | HOWL | Director | Dec 16, 2025 | Sell | $1.05 | 14,548 | $15,275.40 | 2,550,674 | |
| EVNIN LUKE | HOWL | Director | Dec 15, 2025 | Sell | $1.07 | 23,640 | $25,294.80 | 2,550,674 | |
| EVNIN LUKE | HOWL | Director | Dec 9, 2025 | Sell | $1.01 | 44,570 | $45,015.70 | 2,550,674 | |
| EVNIN LUKE | HOWL | Director | Dec 8, 2025 | Sell | $0.99 | 34,041 | $33,700.59 | 2,550,674 |
Compare HOWL vs Leading Stocks
See how HOWL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "HOWL Werewolf Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.